Viridian Therapeutics VRDN
$29.96 −$1.48 (-4.71%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $29.96 0.00%
Open$31.12
Prev close$31.44
Day range$29.87 – $31.75
Volume1.75M
Market cap$3.40B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$25.75M-63.5% YoY
Operating profit-$103.48M-158.6% YoY
Net profit-$101.21M-192.5% YoY
Diluted EPS-$0.81-138.2% YoY
Free cash flow-$103.14M-21.7% YoY
Operating cash flow-$92.77M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin94.1%
Operating margin-1,781.4%
Net margin-1,741.9%
Return on equity-115.0%
Return on assets-57.1%
Return on invested capital-88.1%
Current ratio14.46
Liabilities / assets43.5%
Cash & investments$955.21M
Total debt$242.46M
Net cash (debt)$712.75M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $25.75M | $284,000.00 | $141,000.00 | $70.85M | $132,000.00 |
| Total Operating Revenue | $25.75M | $284,000.00 | $141,000.00 | $70.85M | $132,000.00 |
| Cost of Revenue | $1.53M | – | – | – | – |
| Gross Profit | $24.23M | – | – | – | – |
| Operating Expense | $127.70M | $126.55M | $116.31M | $434.24M | $122.88M |
| Selling and Admin Expenses | $57.61M | $54.98M | $38.68M | $95.32M | $33.67M |
| -General & Admin Expense | $57.61M | $54.98M | $38.68M | $95.32M | $33.67M |
| Research & Development | $70.09M | $71.58M | $77.63M | $338.93M | $89.21M |
| Operating Profit | -$103.48M | -$126.27M | -$116.17M | -$363.40M | -$122.75M |
| Net Non-Operating Interest Income (Expense) | $264,000.00 | $183,000.00 | $4.41M | $22.45M | $4.51M |
| Non-Operating Interest Income | $9.54M | $8.49M | $7.87M | $27.40M | $7.79M |
| Non-Operating Interest Expense | $9.27M | $8.31M | $3.46M | $4.95M | $3.28M |
| Other Income (Expense) | $2.00M | -$1.03M | $6.86M | -$1.66M | -$2.12M |
| Gain on Sale of Security | $2.07M | -$1.19M | $7.53M | – | – |
| Other Non-Operating Income (Expenses) | -$66,000.00 | $156,000.00 | -$672,000.00 | -$1.66M | -$2.12M |
| Pretax Profit | -$101.21M | -$127.12M | -$104.90M | -$342.60M | -$120.36M |
| Net Profit | -$101.21M | -$127.12M | -$104.90M | -$342.60M | -$120.36M |
| Profit from Continuing Operations | -$101.21M | -$127.12M | -$104.90M | -$342.60M | -$120.36M |
| Net Income to Parent Company | -$101.21M | -$127.12M | -$104.90M | -$342.60M | -$120.36M |
| Other Preferred Stock Dividends | -$9.77M | – | -$12.88M | – | – |
| Net Income to Common Stockholders | -$91.44M | -$127.12M | -$92.03M | -$342.60M | -$161.75M |
| Basic EPS | -$0.81 | -$1.05 | -$0.90 | -$3.32 | -$1.08 |
| Diluted EPS | -$0.81 | -$1.05 | -$0.90 | -$3.32 | -$1.08 |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.03B | $1.10B | $789.02M | $899.42M | $899.42M |
| Total Current Assets | $1.01B | $1.08B | $784.74M | $894.23M | $894.23M |
| Cash and Cash Equivalents & Short-Term Investments | $955.21M | $981.53M | $762.18M | $874.65M | $874.65M |
| -Cash and Cash Equivalents | $172.86M | $164.99M | $176.35M | $212.38M | $212.38M |
| -Short Term Investments | $782.35M | $816.54M | $585.84M | $662.27M | $662.27M |
| Receivables | $29.78M | $75.00M | – | – | – |
| -Accounts Receivable | $29.78M | – | – | – | – |
| Inventory | $85,000.00 | – | – | – | – |
| Restricted Cash | $1.30M | – | – | – | – |
| Other Current Assets | $26.76M | $24.74M | $22.56M | $19.58M | $19.58M |
| Total Non-Current Assets | $15.54M | $15.96M | $4.27M | $5.19M | $5.19M |
| Net PPE | $5.62M | $4.85M | $3.39M | $3.65M | $3.65M |
| -Gross PPE | $5.62M | $4.85M | $3.39M | $4.87M | $4.87M |
| Goodwill and Other Intangible Assets | $9.79M | $10.00M | – | – | – |
| Other Non-Current Assets | $131,000.00 | $1.11M | $888,000.00 | $1.54M | $1.54M |
| Total Liabilities | $447.97M | $435.14M | $153.01M | $177.25M | $177.25M |
| Total Current Liabilities | $70.05M | $63.79M | $51.81M | $70.70M | $70.70M |
| Payables | $9.30M | $8.65M | $13.31M | $8.68M | $8.68M |
| -Accounts Payable | $9.30M | $8.65M | $13.31M | $8.68M | $8.68M |
| Current Accrued Expenses | $37.69M | $40.07M | $29.12M | $41.24M | $41.24M |
| Short-Term Debt and Capital Lease Obligation | $806,000.00 | $722,000.00 | $738,000.00 | $753,000.00 | $753,000.00 |
| -Current Capital Lease Obligation | $806,000.00 | $722,000.00 | $738,000.00 | $753,000.00 | $753,000.00 |
| Total Non-Current Liabilities | $377.92M | $371.34M | $101.20M | $106.56M | $106.56M |
| Long Term Debt and Capital Lease Obligation | $242.46M | $242.16M | $50.44M | $49.94M | $49.94M |
| -Long Term Debt | $242.46M | $242.16M | $50.44M | $49.94M | $49.94M |
| Derivative Product Liabilities | $11.62M | $13.69M | $12.50M | $20.03M | $20.03M |
| Non-Current Deferred Liabilities | $121.61M | $113.64M | $36.09M | $34.24M | $34.24M |
| Other Non-Current Liabilities | $2.23M | $1.85M | $2.18M | $2.34M | $2.34M |
| Total Equity | $580.70M | $662.10M | $636.01M | $722.17M | $722.17M |
| Stockholders' Equity | $580.70M | $662.10M | $636.01M | $722.17M | $722.17M |
| Capital Stock | $99.16M | $99.16M | $133.08M | $133.07M | $133.07M |
| -Common Stock | $1.14M | $1.13M | $1.03M | $1.02M | $1.02M |
| -Preferred Stock | $98.02M | $98.02M | $132.06M | $132.06M | $132.06M |
| Additional Paid-In Capital | $2.16B | $2.13B | $1.95B | $1.93B | $1.93B |
| Retained Earnings | -$1.67B | -$1.57B | -$1.44B | -$1.34B | -$1.34B |
| Gains/Losses Not Affecting Retained Earnings | -$2.20M | -$1.15M | -$558,000.00 | $447,000.00 | $447,000.00 |
| -Other Receivables | – | $75.00M | – | – | – |
| Current Deferred Liabilities | – | $181,000.00 | $274,000.00 | $367,000.00 | $367,000.00 |
| -Accumulated Depreciation | – | – | – | -$1.22M | -$1.22M |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$92.77M | -$105.32M | -$119.65M | -$276.39M | -$23.75M |
| Net cash flow from continuing operations | -$92.77M | -$105.32M | -$119.65M | -$276.39M | -$23.75M |
| Net Income from Continuing Operations | -$101.21M | -$127.12M | -$104.90M | -$342.60M | -$120.36M |
| Gain/Loss from Continuing Operations | -$2.41M | $5.64M | -$7.53M | $700,000.00 | – |
| Depreciation & Depletion & Amortization | $343,000.00 | $117,000.00 | $121,000.00 | $460,000.00 | $120,000.00 |
| Other Non-Cash Items | $8.59M | $2.34M | $2.51M | $4.47M | $4.20M |
| Change in Working Capital | -$13.76M | -$1.84M | -$21.39M | $23.03M | $81.35M |
| -Change in Prepaid Assets | -$1.04M | -$2.40M | -$2.33M | $262,000.00 | -$8.59M |
| -Change in Payables and Accrued Expense | $17.31M | $909,000.00 | -$19.06M | $22.77M | $19.94M |
| -Change In Other Working Capital | $106,000.00 | – | – | – | – |
| Net cash flow from investing | $24.34M | -$231.16M | $77.26M | -$37.56M | -$339.42M |
| Net Cash Flow from Continuing Investing Activities | $24.34M | -$231.16M | $77.26M | -$37.56M | -$339.42M |
| Net PPE Purchase and Sale | -$370,000.00 | -$1.31M | -$23,000.00 | -$495,000.00 | -$240,000.00 |
| Net Investment Purchase and Sale | $34.71M | -$229.85M | $77.28M | -$37.07M | -$339.18M |
| Financing Cash Flow | $77.61M | $325.12M | $6.36M | $426.74M | $405.91M |
| Net Cash Flow from Continuing Financing Activities | $77.61M | $325.12M | $6.36M | $426.74M | $405.91M |
| Net Issuance Payments Of Debt | -$250.00M | – | – | $28.88M | $28.88M |
| Net Common Stock Issuance | $0.00 | $143.75M | $0.00 | $352.20M | $337.29M |
| Proceeds from Stock Option Exercised | $3.63M | $1.85M | $6.36M | $14.79M | $8.45M |
| Net Other Financing Charges | $73.98M | – | – | $30.88M | $31.30M |
| Ending Cash Balance | $174.16M | $164.99M | $176.35M | $212.38M | $212.38M |
| Net Change in Cash | $9.17M | -$11.36M | -$36.04M | $112.79M | $42.74M |
| Beginning Cash Balance | $164.99M | $176.35M | $212.38M | $99.59M | $169.65M |
| Free Cash Flow | -$103.14M | -$106.63M | -$119.68M | -$276.89M | -$23.99M |
| Net Preferred Stock Issuance | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on VRDN.
Sign in to join the discussion.